Regina Berkovich MD, PhD Inc. Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2019
NCT04048577
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Berkovich, Regina MD, PhD Inc. | Regina Berkovich MD, PhD Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

natalizumab (tysabri) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Relapsing-Remitting (Phase 4)

Sclerosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1